Meeting
2023 ASCO Annual Meeting
Anti-tumor activity of sunvozertinib in NSCLC with EGFR sensitizing mutations after failure of EGFR TKI treatment.
Authors
James Chih-Hsin Yang
National Taiwan University Hospital, Taipei City, Taiwan
James Chih-Hsin Yang , Yan Xu , Wen-Tsung Huang , Wu-Chou Su , Bo Gao , Chee Khoon Lee , Jian Fang , Wenlei Yu , Mengzhao Wang , Pasi A. Janne
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT05559645 NCT03974022 and CTR20192097
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9103)
DOI
10.1200/JCO.2023.41.16_suppl.9103
Abstract #
9103
Poster Bd #
91
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Antitumor activity of sunvozertinib in NSCLC patients with EGFR Exon20 insertion mutations after platinum and anti-PD(L)1 treatment failures.
First Author: Pasi A. Janne
Poster
2023 ASCO Annual Meeting
Efficacy and safety of sunvozertinib in treatment naïve NSCLC patients with EGFR exon20 insertion mutations.
First Author: Yan Xu
Poster
2023 ASCO Annual Meeting
Aumolertinib with chemotherapy or alone compared with osimertinib in patients with EGFR-mutant non–small-cell lung cancer (TREBLE).
First Author: Melissa Lynne Johnson
Poster
2024 ASCO Annual Meeting
REZILIENT3: Phase 3 study of zipalertinib plus chemotherapy in patients with previously untreated, advanced nonsquamous non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins) mutations.
First Author: Helena Alexandra Yu